The Week Ahead: May 4 – May 8, 2026

Posted on | by Leon Hinde | Leave a Comment on The Week Ahead: May 4 – May 8, 2026

The Week Ahead: May 4 – May 8, 2026

The upcoming week will be dominated by central bank policy and the tail-end of the US earnings season. Investors should focus on the following key events:

1. Macro Data and Central Banks

  • RBA Interest Rate Decision: The market is bracing for a possible 25 basis point (bps) rate hike from the Reserve Bank next week. Persistent cost pressures and the March inflation print of 4.6% have led analysts to forecast that rates could rise to 4.60% by September 2026.
  • US Fed Watch: With the Fed Funds Interest Rate currently at 3.75%, any commentary following the recent PCE data will be scrutinized for signs of a pivot or continued pause.

2. Company Events and Earnings

ASX Resource Reports: Following BHP’s recent Quarterly Activities Report, market participants will be looking for production guidance updates from mid-tier miners as commodity price volatility continues.

US Earnings: The earnings season continues with key players in the energy and consumer discretionary sectors scheduled to report. The focus will remain on whether corporate margins can continue to withstand higher interest costs.

CSL

Posted on | by Leon Hinde | Leave a Comment on CSL

CSL is navigating a period of significant structural transition and market re-evaluation. The stock recently hit a nine-year low, primarily driven by a sharp earnings reset in its half-year results and broader regulatory headwinds.

Valuation: The price-to-earnings (P/E) ratio has compressed to approximately 15x (TTM) on an underlying basis.

Recent Financial Performance (H1 FY26)
The company’s February 2026 earnings report was a major catalyst for the recent sell-off:

  • Net Profit Plunge: Reported Net Profit After Tax (NPAT) fell 81% to US$401 million, largely due to ~US$1.1 billion in one-off restructuring charges and asset impairments.
  • Underlying Performance: Underlying NPATA fell 7% to US$1.9 billion.
  • Revenue: Declined 4% to US$8.3 billion (constant currency). The core CSL Behring plasma division saw a 7% sales contraction, driven by U.S. Medicare reimbursement reforms and policy changes in China affecting pricing.
  • Impairments: Significant write-downs were taken on CSL Vifor (primarily due to generic competition for its iron therapy, Venofer®) and intellectual property within CSL Seqirus.

Strategic Developments & Recovery Plan
Despite the earnings volatility, management is aggressively deploying capital to stabilize margins:

  • Capacity Expansion: In March 2026, CSL broke ground on a US$1.5 billion expansion of its Kankakee, Illinois facility. This project will utilize “Horizon 2” technology designed to increase protein yield from plasma.
  • Share Buy-back: CSL is currently active in an on-market share buy-back program. As of today, April 27, 2026, the company has repurchased nearly 6 million shares to support shareholder value.
  • Cost Savings: CSL has targeted US$500M+ in annual pre-tax savings by FY28 through organizational simplification.
  • Vaccine Pipeline: CSL Seqirus recently secured new long-term contracts with the Pan American Health Organization (PAHO) and Canada for pandemic influenza preparedness.

Dividends & Guidance

  • Dividends: The interim dividend of US$1.30 per share (unfranked) was paid on April 8, 2026. The current annual yield sits at approximately 3.3%.
  • FY26 Outlook: Management has maintained guidance for the full year 2026, expecting 2–3% revenue growth and 4–7% NPATA growth (excluding one-offs). However, the market remains cautious about the “structural” nature of margin pressures through FY28.

Investor Outlook
The current market sentiment is a battle between value seekers (pointing to “oversold” technical indicators and a 15-year low multiple) and skeptics concerned about the long-term impact of U.S. Medicare drug price negotiations and competition in the iron deficiency market.

Snowflake

Posted on | by Leon Hinde | Leave a Comment on Snowflake

Snowflake remains one of the highest-quality data + AI infrastructure platforms globally, positioned at the centre of enterprise data workflows.

The investment case is simple:

  • Structural tailwind: Explosion in data + AI workloads
  • Platform leverage: Usage-based model scales with customer success
  • Margin expansion: Strong operating leverage as revenue scales

👉 The market is pricing Snowflake as a ~25–30% revenue compounder with accelerating earnings power

📊 Revenue Growth Profile

MetricCurrentForward View
Revenue Growth~30% YoY~25–27% YoY
FY2026 Revenue~$4.7B—
Medium-Term Target—~$8–9B (next ~3–4 yrs)

Key Drivers

  • Enterprise data migration to cloud
  • AI / machine learning workloads
  • Expansion within existing customers (land → expand model)

👉 Takeaway:
Revenue growth is high but normalising, still well above most large-cap software peers.

Based on current market estimates as of April 30, 2026, Snowflake (SNOW) is expected to report its fiscal first quarter 2027 results in late May.

Estimated Earnings Date

  • Primary Estimate: Wednesday, May 27, 2026 (After market close).
  • Secondary Estimate: Some analysts project the release could occur as early as Wednesday, May 20, 2026.
  • Official Confirmation: Snowflake typically issues a press release confirming the exact date and time in early May (last year, the announcement was made on May 1st).

Q1 FY2027 Analyst Expectations
Analysts are currently forecasting the following metrics for the quarter ending April 30, 2026:

Implied Growth: This would represent approximately 27% year-over-year revenue growth.

Consensus EPS Forecast: ~$0.32 (estimates range from $0.14 to $0.32 depending on the source).

Revenue Forecast: ~$1.32 billion.

CSL

Posted on | by Leon Hinde | Leave a Comment on CSL

CSL is navigating a period of significant structural transition and market re-evaluation. The stock recently hit a nine-year low, primarily driven by a sharp earnings reset in its half-year results and broader regulatory headwinds.

Valuation: The price-to-earnings (P/E) ratio has compressed to approximately 15x (TTM) on an underlying basis.

Recent Financial Performance (H1 FY26)
The company’s February 2026 earnings report was a major catalyst for the recent sell-off:

  • Net Profit Plunge: Reported Net Profit After Tax (NPAT) fell 81% to US$401 million, largely due to ~US$1.1 billion in one-off restructuring charges and asset impairments.
  • Underlying Performance: Underlying NPATA fell 7% to US$1.9 billion.
  • Revenue: Declined 4% to US$8.3 billion (constant currency). The core CSL Behring plasma division saw a 7% sales contraction, driven by U.S. Medicare reimbursement reforms and policy changes in China affecting pricing.
  • Impairments: Significant write-downs were taken on CSL Vifor (primarily due to generic competition for its iron therapy, Venofer®) and intellectual property within CSL Seqirus.

Strategic Developments & Recovery Plan
Despite the earnings volatility, management is aggressively deploying capital to stabilize margins:

  • Capacity Expansion: In March 2026, CSL broke ground on a US$1.5 billion expansion of its Kankakee, Illinois facility. This project will utilize “Horizon 2” technology designed to increase protein yield from plasma.
  • Share Buy-back: CSL is currently active in an on-market share buy-back program. As of today, April 27, 2026, the company has repurchased nearly 6 million shares to support shareholder value.
  • Cost Savings: CSL has targeted US$500M+ in annual pre-tax savings by FY28 through organizational simplification.
  • Vaccine Pipeline: CSL Seqirus recently secured new long-term contracts with the Pan American Health Organization (PAHO) and Canada for pandemic influenza preparedness.

Dividends & Guidance

  • Dividends: The interim dividend of US$1.30 per share (unfranked) was paid on April 8, 2026. The current annual yield sits at approximately 3.3%.
  • FY26 Outlook: Management has maintained guidance for the full year 2026, expecting 2–3% revenue growth and 4–7% NPATA growth (excluding one-offs). However, the market remains cautious about the “structural” nature of margin pressures through FY28.

Investor Outlook
The current market sentiment is a battle between value seekers (pointing to “oversold” technical indicators and a 15-year low multiple) and skeptics concerned about the long-term impact of U.S. Medicare drug price negotiations and competition in the iron deficiency market.

Inner Circle

Posted on | by Leon Hinde | Leave a Comment on Inner Circle

Zscaler, Inc. – Common is expected to report its fiscal third quarter (Q3) 2026 earnings on 28 May. Investors will likely focus on whether the company can maintain its record-high non-GAAP operating margins (22.4% in Q2).

AI Security Growth: Updates on the “AI-driven security moat” and transaction volume. Acquisition Integration: Performance of the recently acquired Red Canary.

Analyst Expectations

  • Estimated EPS: ~$1.00 – $1.01
  • Estimated Revenue: ~$831 million – $836 million

Last Earnings Recap (Q2 FY2026)

  • Report Date: February 26, 2026
  • Results: Zscaler reported a strong beat with an EPS of $1.01 (vs. $0.89 expected) and revenue of $815.75 million (vs. $798.33 million expected).
  • Guidance: Following the Q2 report, the company raised its full-year fiscal 2026 revenue guidance to approximately $3.32 billion.

Inner Circle

Posted on | by Leon Hinde | Leave a Comment on Inner Circle

Honeywell International Inc. – Common is currently a “transformation play.” While near-term revenue headwinds and supply chain issues are weighing on the stock, the June 29 Aerospace spin-off is the primary catalyst we’re watching.

Q1 2026 Earnings Highlights (Released April 23, 2026)
Honeywell reported mixed results for the first quarter of 2026:

  • Adjusted EPS: $2.45, beating the analyst consensus of $2.32 (up 11% year-over-year).
  • Revenue: $9.14 billion, missing the estimated $9.30 billion. Organic sales growth was 2%, slowed by mechanical supply chain constraints in Aerospace and geopolitical disruptions in the Middle East.
  • Margins: Segment margins expanded 90 basis points to 23.3%, driven by strong pricing discipline and cost removals.
  • Backlog: Rose 15% to a robust $38 billion, indicating strong future demand.

Strategic Catalyst: The Aerospace Spin-Off
The biggest upcoming driver for HON is the planned separation of its Aerospace business:

  • Spin-Off Date: Scheduled for June 29, 2026.
  • Objective: To create two “pure-play” companies: one focused on Aerospace Technologies and the other (RemainCo) on Industrial/Building Automation and Energy.
  • Divestitures: Honeywell also recently announced the sale of its Warehouse and Workflow Solutions (WWS) and Productivity Solutions and Services (PSS) businesses, expected to close in the second half of 2026.

Fundamental Metrics & Valuation

  • Price-to-Earnings (P/E) Ratio: ~26.5x (Trailing).
  • Forward P/E: ~19.6x.
  • Dividend Yield: ~2.27% ($4.76 annualized).
  • Full-Year 2026 Guidance:

* Sales: $38.8B – $39.8B (3-6% organic growth).
* Adjusted EPS: $10.35 – $10.65.
* Free Cash Flow: $5.3B – $5.6B.

Analyst Outlook

  • Consensus: “Moderate Buy” with 13 Buy ratings and 8 Hold ratings.
  • Price Targets: Analysts have a median target of $245.00 – $250.21, implying a potential upside of roughly 15-20% from current levels.
  • Recent Changes: Following the revenue miss, firms like Citigroup and Barclays slightly lowered their price targets (e.g., Citi from $265 to $257) but maintained “Buy/Overweight” ratings, citing long-term value in the portfolio breakup.

Intuitive Surgical

Posted on | by Leon Hinde | Leave a Comment on Intuitive Surgical

{NAS.ISRG} is a dominant leader in the robotic-assisted surgery market, known for its da Vinci surgical systems.

Earnings Alert: Q1 2026

  • Release Date: Tomorrow, April 21, 2026, after market close.
  • Estimates: Analysts expect EPS of approximately $2.08 – $2.16 on revenue of $2.61 – $2.67 billion.

Key Focus: Investors will be watching for updates on the rollout of the da Vinci 5* and commentary on 2026 procedure growth guidance (currently 13–15%).

Fundamental Metrics

  • Market Cap: ~$166.65 Billion.
  • Valuation:

* Forward P/E: 41.06x
* Trailing P/E: 59.54x
* Price-to-Book: 9.35x

  • Analyst Sentiment: Rated as a Buy (Average Rating: 1.9) with a median price target generally cited near $600, implying significant potential upside from current levels.

Recent Developments & Catalysts
FDA Expansions: In early 2026, the company received FDA clearance for the da Vinci 5for select cardiac procedures and recently expanded da Vinci SP* indications to include inguinal hernia and appendectomy.

  • Operational Milestone: The company reached a milestone of 20 million procedures performed globally in January 2026, reinforcing its massive “razor-and-blade” recurring revenue model (instruments and accessories).
  • Guidance Caution: The stock has seen some pressure in early 2026 due to conservative procedure growth guidance (13-15% vs. 18% in 2025), as the company laps tough year-over-year comparisons.

Performance Context

  • 52-Week Range: $427.84 – $603.88.
  • Technical Trend: The stock is currently trading below its 200-day moving average ($503.09), suggesting it is in a period of consolidation or correction ahead of its earnings results. It has underperformed the broader S&P 500 YTD by approximately 18%.

Actionable Insight: ISRG remains a high-quality growth play, but current valuation multiples reflect high expectations. Tomorrow’s earnings call will be critical to determine if the 2026 growth deceleration is fully priced in.

US Earnings

Posted on | by Leon Hinde | Leave a Comment on US Earnings

Monday, April 20: Steel Dynamics.

Tuesday, April 21: GE Aerospace, 3M, Halliburton, United Airlines.

Wednesday, April 22: Tesla, Philip Morris), IBM, Boeing.

Thursday, April 23: Intel, American Express, Blackstone.

Friday, April 24: P&G.

Here’s a very brief, revenue + profit growth–focused snapshot of that earnings week:

Monday (Apr 20) – Steel Dynamics

  • Revenue: ~$5.2B (+19% YoY)
  • Profit (EPS): $2.78 (~+90% YoY)
  • Takeaway: Strong cyclical upswing — pricing + volumes drove outsized profit leverage.

Tuesday (Apr 21) – Industrials & Cyclicals

  • GE Aerospace: Strong revenue beat; earnings growth driven by aerospace demand (sector leader in Industrials growth).
  • 3M: Modest growth; restructuring still limiting profit expansion.
  • Halliburton: Mixed; energy sector seeing earnings pressure vs last year.
  • United Airlines: Solid revenue recovery; margins improving with travel demand.

Takeaway: Industrials strong; energy lagging.

Wednesday (Apr 22) – Mixed Growth Profiles

  • Tesla:
    • Revenue ~+16% YoY, profit ~+17% YoY
    • Growth intact but slowing vs prior years
  • IBM: Low-single-digit growth; steady margins.
  • Boeing: Recovery phase; revenue improving but profitability still volatile.
  • Philip Morris International: Stable revenue growth; margin resilience.

Takeaway: Growth present but more selective vs 2023–24 tech boom.

Thursday (Apr 23) – Tech + Financial Strength

  • Intel:
    • Revenue beat; strong AI/data centre demand
    • Profit improving (adjusted EPS beat)
    • Forward growth accelerating
  • American Express: Solid revenue growth; resilient consumer spend.
  • Blackstone: Earnings growth tied to asset inflows and higher fee income.

Takeaway: AI + financials driving earnings momentum.

Friday (Apr 24) – Defensive Consumer

  • Procter & Gamble:
    • Revenue growth steady
    • EPS guidance stable but cost pressures limiting upside

Takeaway: Defensive names = stable but low growth.

Overall Week (Key Investment Signal)

Laggards: Energy, defensive consumer

Revenue growth: ~mid-to-high single digit overall (S&P ~10%)

Earnings growth: ~mid-teens (~15%)

Leaders: Industrials, AI/tech, materials

Taiwan Semiconductor Manufacturng

Posted on | by Leon Hinde | Leave a Comment on Taiwan Semiconductor Manufacturng

TSMC (TSM) recently reported exceptionally strong Q1 2026 results on April 16, 2026, leading to a revised upward outlook for the remainder of the year. The stock is currently trading near all-time highs as AI-driven demand continues to outpace supply.

Q1 2026 Earnings Performance
TSMC’s most recent quarterly report beat expectations across all major metrics:

  • Revenue: $35.9 billion (NT$1,134.1 billion), a 35.1% increase year-over-year.
  • EPS: $3.49 per ADR (NT$22.08), exceeding analyst consensus of ~$3.35.
  • Profitability: Gross margins reached 66.2% and operating margins hit 58.1%, both exceeding the company’s own prior guidance due to higher capacity utilization and cost-cutting measures.
  • Advanced Technology: Revenue from 3nm and 5nm nodes accounted for 50% of total wafer revenue, signaling a successful transition to the most advanced manufacturing processes.

2026 Outlook & Guidance
The company has significantly raised its full-year expectations:

  • Full-Year Revenue: Guidance was upgraded to “above 30%” growth (previously mid-20s).
  • Q2 2026 Guidance: Revenue is expected between $39.0B and $40.2B, representing continued sequential growth.
  • CapEx: 2026 capital expenditures are refined to $52B – $56B, indicating aggressive investment in 2nm production and the newly announced A16 (1.6nm) process technology.

Valuation Metrics

  • Trailing P/E: 31.86x
  • Forward P/E: 19.35x (indicates strong expected earnings growth in the coming 12 months).
  • Dividend Yield: ~0.95% ($3.51/share annually).

Key Investment Considerations

TSMC remains the sole provider for high-end AI chips (NVIDIA, Apple, AMD). The ramp-up of 2nm production in late 2026 is expected to provide a multi-year growth runway.

    Actionable Insight: For long-term investors, the significant upgrade in revenue guidance suggests the AI cycle has more legs. However, at $370+, the stock is approaching some analysts’ price targets (e.g., Needham at $480), suggesting new entries might wait for minor pullback.

    US Earnings

    Posted on | by Leon Hinde | Leave a Comment on US Earnings

    Here’s a clean, investor-focused snapshot of revenue and EPS growth (YoY) from that week’s earnings releases:

    Monday, April 13

    Goldman Sachs

    • Revenue: Strong growth (~+15–20% YoY) driven by trading (FICC + equities) and investment banking rebound
    • EPS: Significant beat, +20–30% YoY
    • Takeaway: Capital markets activity clearly improving vs last year’s weak base

    Tuesday, April 14

    JPMorgan Chase

    • Revenue: Solid growth (~+8–10% YoY), helped by net interest income and markets
    • EPS: +10–15% YoY
    • Takeaway: Still best-in-class execution; benefiting from scale and higher rates

    Johnson & Johnson

    • Revenue: Modest growth (~+3–5% YoY)
    • EPS: Flat to slightly up (~0–5% YoY)
    • Takeaway: Defensive, steady—not a growth story this quarter

    Wells Fargo

    • Revenue: Flat to slightly up (~0–3% YoY)
    • EPS: Slight increase (~+5–10% YoY)
    • Takeaway: Cost control helping EPS despite muted top-line

    Citigroup

    • Revenue: Modest growth (~+3–6% YoY)
    • EPS: +10–15% YoY (efficiency + restructuring benefits)
    • Takeaway: Early signs turnaround gaining traction

    Wednesday, April 15

    ASML

    • Revenue: Strong growth (~+20% YoY)
    • EPS: +25–30% YoY
    • Takeaway: AI-driven semiconductor capex cycle clearly accelerating

    Bank of America

    • Revenue: Slight decline or flat (~-2% to 0% YoY)
    • EPS: Down slightly (~-5% YoY)
    • Takeaway: Pressure from deposit costs and weaker NII

    Morgan Stanley

    • Revenue: Moderate growth (~+5–8% YoY)
    • EPS: +10–15% YoY
    • Takeaway: Wealth + investment banking recovery supporting growth

    Thursday, April 16

    Taiwan Semiconductor Manufacturing Company

    • Revenue: Strong rebound (~+15–20% YoY)
    • EPS: +20–25% YoY
    • Takeaway: AI demand (advanced nodes) driving cyclical upturn

    Netflix

    • Revenue: Solid growth (~+12–15% YoY)
    • EPS: Strong growth (+20%+ YoY)
    • Takeaway: Pricing + ad tier + subscriber momentum driving operating leverage

    PepsiCo

    Takeaway: Pricing-led growth, volume still soft

    Revenue: Low single-digit growth (~+2–4% YoY)

    EPS: Mid-single-digit growth (~+5–8% YoY)

    Monday, April 13: Goldman Sachs

    Tuesday, April 14: JPMorgan, J&J, Wells Fargo, Citigroup

    Wednesday, April 15: ASML, Bank of America, Morgan Stanley

    Thursday, April 16: Taiwan Semiconductor, Netflix, PepsiCo